Biohaven’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Biohaven is a pharmaceutical company that researches and develops novel drugs for the treatment of neurological and neuropsychiatric diseases. Read more

Vlad Coric's photo - CEO of Biohaven

CEO

Vlad Coric

CEO Approval Rating

92/100

Founded:

2013

Status:

PublicNYSEBHVN

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Covis Pharma is seen as one of Biohaven's biggest rivals. Covis Pharma is headquartered in Baarn, Utrecht, and was founded in 2011. Like Biohaven, Covis Pharma also works within the Pharmaceuticals sector. Covis Pharma generates 525% the revenue of Biohaven.

Neuropore is seen as one of Biohaven's top competitors. Neuropore was founded in 2008, and its headquarters is in San Diego, California. Neuropore operates in the Pharmaceuticals industry. Neuropore has 38 fewer employees than Biohaven.

MODAG is one of Biohaven's top rivals. MODAG is a Private company that was founded in Wendelsheim, Rhineland-Palatinate in 2013. MODAG operates in the Biotechnology industry. MODAG has 27 more employees vs. Biohaven.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is ProMIS a competitor of Biohaven?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$10.8M

Biohaven's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 1.2B. Over the last four quarters, Biohaven's revenue has grown by 742.6%. Specifically, in Q2 2020's revenue was $9.7M; in Q1 2020, it was $1.2M; in Q4 2019, it was $1.2M; in Q3 2019, Biohaven's revenue was $1.2M.

Acquisitions

No recent acquisitions found related to Biohaven

Biohaven Funding History

$80M$248.3M$748.3M

Since Biohaven was founded in 2013, it has participated in 3 rounds of funding. In total Biohaven has raised $748.3M. Biohaven's last funding round was on Aug 2020 for a total of $500.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2020
$500M

Sixth Street Partners

IPO
May 2017
$168.3M
-
Equity
Oct 2016
$80M

Total Funding: $748.3M

Since Biohaven was founded in 2013, it has participated in 3 rounds of funding. In total Biohaven has raised $748.3M. Biohaven's last funding round was on Aug 2020 for a total of $500.0M

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Kleo is a biotechnology company that develops and markets antibody therapeutics for the treatment of cancer and infectious diseases.
$13.5M
Aug 28, 2016
Series A
-

Biohaven News

August 13, 2020Zolmax News

Equities Analysts Issue Forecasts for Biohaven Pharmaceutical Holding Co Ltd's FY2020 Earnings (NYSE:BHVN)

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) - Investment analysts at Cantor Fitzgerald issued ... See more »
August 10, 2020ABF Journal

Sixth Street Delivers $500MM Term Loan to Biohaven

Sixth Street provided a $500 million non-dilutive term loan financing facility for Biohaven Pharmaceu... See more »
August 7, 2020The Pharma Letter

Biohaven secures $250 million funding for CGRP receptor antagonist

A funding agreement between Biohaven Pharmaceutical and Royalty Pharma will provide up to $250 millio... See more »
August 7, 2020OINDPnews

Royalty Pharma provides funding for Biohaven's zavegepant development program

Biohaven Pharmaceutical will receive up to $250 million from Royalty Pharma on closing of a deal to f... See more »

Biohaven Press Releases

February 25, 2020StreetInsider

Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments

NEW HAVEN, Conn., Feb. 25, 2020 /PRNewswire/Â --Â Biohaven Pharmaceutical Holding Company Ltd. (NYSE:... See more »
February 10, 2020centralcharts

Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List

Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List PR Newswire... See more »
November 5, 2019centralcharts

Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole

Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole ... See more »
November 5, 2019StreetInsider

Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board

NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ --Â Biohaven Pharmaceutical Holding Company Ltd. (NYSE: B... See more »
December 10, 2018central charts

Biohaven Announces Proposed Public Offering of Common Shares

NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: B... See more »
March 28, 2018MarketersMedia

Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant

Stock Monitor: Cytori Therapeutics Post Earnings ReportingLONDON, UK / ACCESSWIRE / March 28, 2018 / ... See more »

Biohaven Videos

October 16, 2019Biohaven Vimeo Channel

"012419_BHPBIO22918_GlutamatePlatformModifcation_Final_c01" on VIMEO

Cast: Biohaven Pharmaceuticals... See more »
October 14, 2019Biohaven Vimeo Channel

"Patient 4 assessment 10" on VIMEO

Cast: Biohaven Pharmaceuticals... See more »
October 14, 2019Biohaven Vimeo Channel

"UMSARS Healthy Control Assessment" on VIMEO

Cast: Biohaven Pharmaceuticals... See more »
October 1, 2019Biohaven Youtube Channel

"OCD Documentary - Trailer" on YOUTUBE

Headquarters

215 Church Street

New Haven, Connecticut06510

203-404-0410

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Biohaven is a pharmaceutical company that researches and develops novel drugs for the treatment of neurological and neuropsychiatric diseases. Biohaven was founded in 2013. Biohaven's headquarters is located in New Haven, Connecticut, USA 06510. It ha...

CEO

Biohaven's CEO, Vlad Coric, currently has an approval rating of 92%. Biohaven's primary competitors are Covis Pharma, Neuropore & MODAG.

Website

biohavenpharma.com

Frequently Asked Questions about Biohaven

  1. When was Biohaven founded?

    Biohaven was founded in 2013
  2. Who is Biohaven's CEO?

    Biohaven's CEO is Vlad Coric
  3. How much revenue does Biohaven generate?

    Biohaven generates $10.8M in revenue
  4. How much funding does Biohaven have?

    Biohaven has historically raised $748.3M in funding
  5. Where is Biohaven's headquarters?

    Biohaven's headquarters is in New Haven Connecticut, USA
  1. How many employees does Biohaven have?

    Biohaven has 63 employees
  2. What sector does Biohaven operate in?

    Biohaven is in Biotechnology, Pharmaceuticals
  3. Who are Biohaven's competitors?

    Biohaven's top competitors are Covis Pharma, Neuropore, MODAG
  4. Who has Biohaven invested in?

    Biohaven's has invested in companies such as Kleo